AstraZeneca blows past analysts' estimates for Q1 : vimarsan

AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Related Keywords

Pascal Soriot , Hargreaves Lansdown , Derren Nathan , Astrazeneca , Blows , Past , Analysts 039 , Estimates , Category All , Category Company News , Category News And Announcements , Category Tecnologia , Category Headline News , Category Sectorial Health Technology , Mostread Technology ,